Cognition Therapeutics Inc. (CGTX)
NASDAQ: CGTXHealthcareBiotechnologyUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
CGTX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $85.13M
- EPS (TTM)
- -$0.17
- Dividend yield
- None
- 52-week range
- 0.55 – 2.05
- Day range
- 0.8945 – 0.9483
- Volume / Avg
- 452.68K / 558.54K
- Beta
- —
- Shares outstanding
- 95.09M
- Next earnings
- Nov 5, 2026
52-week range
CGTX stock today
On Oct 8, CGTX ended the session at $0.8952, shedding $0.0414 (4.42%), versus the S&P 500's 0.47% decline. At this level, CGTX sits in the middle of its 52-week range of $0.55 to $2.05: 56.3% below the high, set on Oct 10, 2025 and 62.8% above the low. CGTX is down 30.6% year to date, underperforming the S&P 500 (+13.5%). Over the past 12 months, the stock has lost 46.5%.
Cognition Therapeutics has posted a net loss over the last twelve months (EPS of -$0.17), so its P/E ratio is not meaningful. Cognition Therapeutics's next earnings report is expected on Nov 5, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Cognition Therapeutics
Company profileCognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is zervimesine, an orally delivered small molecule to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, which is in Phase 2 clinical studies for the treatment of Alzheimer's disease and Mild Cognitive Impairment, as well as geographic atrophy secondary to dry age-related macular degeneration and dementia with Lewy bodies. Cognition Therapeutics, Inc.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Ms. Lisa Ricciardi
- Headquarters
- Purchase, NY
- Employees
- 14
- IPO year
- 2021
- Website
- cogrx.com
Analyst forecast
ForecastConsensus (3 analysts)
strong_buy
Avg. price target
$3.33+271.98%
- Strong buy 0
- Buy 3
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 5, 2026
- EPS estimate
- $-0.07
Cognition Therapeutics peers
Healthcare sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| NRXSNeuraxis Inc. | 6.77 | -0.88% | $85.02M | vs CGTX |
| TELOTelomir Pharmaceuticals Inc. | 1.15 | +2.68% | $84.66M | vs CGTX |
| CRDFCardiff Oncology Inc. | 1.06 | -2.75% | $82.46M | vs CGTX |
| PMNProMIS Neurosciences Inc. | 9.15 | +0.33% | $82.05M | vs CGTX |
| ICCCImmuCell Corporation | 9.75 | +0.62% | $88.55M | vs CGTX |
| MISTMilestone Pharmaceuticals Inc. | 0.7121 | -5.96% | $88.66M | vs CGTX |
| ACRVAcrivon Therapeutics Inc. | 1.87 | -0.53% | $80.14M | vs CGTX |
| NMRANeumora Therapeutics Inc. | 0.4798 | +2.46% | $90.15M | vs CGTX |
Indexes, lists and sector
Appears in lists
Cognition Therapeutics stock FAQ
What is Cognition Therapeutics's stock price today?
CGTX last traded at $0.8952 as of Oct 8, 4:00 PM EDT, down 4.42% on the day. Prices are delayed at least 15 minutes.
When is Cognition Therapeutics's next earnings date?
Cognition Therapeutics is expected to report earnings on Thursday, November 5, 2026. Analysts expect EPS of $-0.07.
Who is Cognition Therapeutics's CEO?
Ms. Lisa Ricciardi is the chief executive officer of Cognition Therapeutics Inc., which has about 14 employees.
What is the CGTX 52-week high?
The 52-week high for CGTX is $2.05 and the 52-week low is $0.55. The stock is currently 56.3% below its high.